Johnson & Johnson’s Revolutionary Study on Blood Clots Sheds Light on Stroke Care: The Excellent Registry

In 2018, Johnson & Johnson embarked on a mission to transform the way blood clots are studied. Their aim was to determine how various clot characteristics such as size, composition, and density could impact patient outcomes. The company also wanted to analyze the effectiveness of two of their medical devices in clot removal.

To achieve these goals, Johnson & Johnson conducted a study involving 1,000 stroke patients at 36 clinical trial sites around the world. They collected actual blood clots that had been removed from stroke patients and analyzed them using advanced imaging technology. Independent evaluators reviewed the data and provided insights into the impact of different clot characteristics on patient outcomes.

The resulting registry, known as the Excellent Registry, is the largest acute ischemic stroke registry globally. It collects patient data, imaging information, and clot information on a per-pass basis, with independent evaluators reviewing the data to ensure accuracy and objectivity. This initiative highlights Johnson & Johnson’s dedication to innovation in advancing stroke care.

Given that every 40 seconds someone in the United States has a stroke and every 3.5 minutes someone dies from one, Johnson & Johnson’s commitment to improving stroke care is crucial. Their efforts have the potential to save countless lives and improve health outcomes for millions of people worldwide.